Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neurobehavioral Manifestations, Neurologic Manifestations, Rett syndrome, X-linked disease, hereditary disease, inherited neurodegenerative disorder, intellectual disability, nervous system disorderRecruitingPhase 1 / Phase 22026-10-08NCT06430385

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Ionis Pharmaceuticals, Inc.22

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Baylor College of MedicineHoustonUnited States306
Boston Children's HospitalBostonUnited States343
British Columbia Children's HospitalVancouverCanada1
Children's Hospital of PhiladelphiaPhiladelphiaUnited States434
CHU Dijon BourgogneDijonFrance12
Gillette Children's Specialty HealthcareSaint PaulUnited States11
Hospital Saint Joan de DeuBarcelonaSpain1
Kennedy KriegerBaltimoreUnited States1
Kepler University HospitalLinzAustria1
Rady Children's HospitalSan DiegoUnited States52
University of Colorado Hopsital - Anschutz Medical CampusAuroraUnited States1
Vanderbilt University Medical CenterNashvilleUnited States427